Iaso Bio Announces Licensing Partnership with Korea's GC Cell to Bring Anti-BCMA CAR-T Therapy Fucaso® to Multiple Myeloma Patients in Korea

Oct 29, 2025 16:19 CST Updated 16:19

IASO Biotechnology

Cancer Treatment New Drug Developer

GC Cell

Cellular Immunotherapy Drug Developer

■ Expected to bring new treatment options for multiple myeloma patients in South Korea.

■ Increase patient access to this therapy in Korea through competitive pricing.

October 29, 2025, IASO Bio announced todayHas signed a cooperation agreement with GC Cell, joining hands to promote the CAR-T cell therapy product Fokos^®(IASO Bio's Idecabtagene Vicleucel Injection) Enters the Korean Market, used for the treatment of multiple myeloma. This collaboration aims to provide new treatment options for patients with multiple myeloma in South Korea; GC Cell plans to progressively advance the registration and commercialization process of Focux® in South Korea based on this.

Signing Ceremony Group Photo: GC Cell Co-CEOSungyong Won(Left) and Zhang Jinhua, Founder, Chairman, and CEO of IASO Bio (Right)

Multiple Myeloma: A Hard-to-Cure Blood Cancer with High Recurrence Risk, Common Among the Elderly

Focasol^®It is a CAR-T cell therapy independently developed by IASO Bio, targeting BCMA (B-cell maturation antigen), which was approved for marketing by the China National Medical Products Administration in June 2023. By implementing a competitive pricing strategy in South Korea, this innovative therapy is expected to significantly improve patient access locally.

To Promote Fokasun^®Entering the South Korean market, GC Cell helped the therapy obtain orphan drug designation granted by the South Korean Ministry of Food and Drug Safety (MFDS) in July this year. In August, Focuxol^®Further designated as a "Fast Track Advanced Therapy Medicinal Product" by South Korean regulatory authorities, accelerating the review and development process. Relying on a stable supply chain, GC Cell is committed to ensuring that patients can access this therapy in a more timely and affordable manner.

Sungyong Won

GC Cell Co-CEO

As a leading cell therapy company in South Korea, this collaboration marks an important first step for GC Cell on the path to commercializing CAR-T therapy. We will fully ensure the stability of the supply chain, enabling patients to access treatment opportunities at a more reasonable cost.

Ms. Zhang Jinhua

Founder, Chairman and Chief Executive Officer of IASO Bio

This collaboration represents an important milestone in our globalization strategy, not only demonstrating the potential of Forxiga® in the international market but also enabling us to leverage GC Cell's outstanding registration and commercialization capabilities in the Korean market. By combining our strengths, we can jointly advance this innovative therapy to benefit more patients in need.

Group photo of representatives from both sides after the signing ceremony

About GC Cell

GC Cell is a leading biotechnology company in South Korea, specializing in the field of immune cell therapy. Its business covers CAR-NK, CAR-T, and CIK cell platforms, while providing CDMO services for cell and gene therapies. With deep expertise in the production and commercialization of autologous and allogeneic cell therapies, GC Cell is continuously expanding its global business footprint through strategic collaborations and ongoing innovation in next-generation cell therapies.